Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

RedHill Biopharma (RDHL) EBT (2016 - 2023)

RedHill Biopharma has reported EBT over the past 12 years, most recently at $58.9 million for Q2 2023.

  • Quarterly EBT rose 791.8% to $58.9 million in Q2 2023 from the year-ago period, while the trailing twelve-month figure was -$40.0 million through Jun 2023, up 64.44% year-over-year, with the annual reading at -$8.1 million for FY2025, 2344.44% down from the prior year.
  • EBT was $58.9 million for Q2 2023 at RedHill Biopharma, up from -$7.9 million in the prior quarter.
  • Over five years, EBT peaked at $58.9 million in Q2 2023 and troughed at -$145.2 million in Q4 2021.
  • The 5-year median for EBT is $11.1 million (2019), against an average of -$1.3 million.
  • Year-over-year, EBT plummeted 1062.84% in 2021 and then skyrocketed 791.8% in 2023.
  • A 5-year view of EBT shows it stood at $11.8 million in 2019, then increased by 27.44% to $15.1 million in 2020, then plummeted by 1062.84% to -$145.2 million in 2021, then soared by 52.14% to -$69.5 million in 2022, then surged by 184.75% to $58.9 million in 2023.
  • Per Business Quant, the three most recent readings for RDHL's EBT are $58.9 million (Q2 2023), -$7.9 million (Q1 2023), and -$69.5 million (Q4 2022).